

FORM PTO 1449
(REV 2-32)

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

File No. 97-72C5

Serial No.

10 789 251

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant(s):

Darrell C. Conklin, Betty A. Haldeman

Filing Date:

February 27, 2004

Group:

1646

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

PM	A2		Incyte Pharmaceuticals Inc., INC819592, March 5, 1996.
	A3		Incyte Pharmaceuticals Inc., INC4304592, July 9, 1998.
	A4		Wuyts et al., "Isolation of the CXC chemokines ENA-78, GRO α and GRO γ from tumor cells and leukocytes reveals NH ₂ -terminal heterogeneity. Functional comparison of different natural isoforms," <u>Eur J. Biochem</u> 260:421-429, 1999.
	A5		Rohovsky et al., "Growth factors and angiogenesis in wound healing," Growth Factors Wound Healing, Eds: Ziegler T.R., Pierce G.F., Herndon D.N.; Pub: Springer New York N.Y., pages 8-26, 1997.
	A6		Diavin, "Cytokines and tissue repair," <u>J. Immunol. Immunopharmacol.</u> 17(1):25-29, 1997.
	A7		George et al., "Macromolecular Sequencing & Synthesis," pages 127-149, Ch. 12, Alan R. Liss, Inc., 1988.
	A8		Harlow et al., "Antibodies A Laboratory Manual," page 76, Ch. 5, Cold Springs Harbor Laboratory, 1988.
	A9		Cunningham et al., <u>Science</u> 244:1081-1085, 1989.

Examiner

Prema Mend

Date considered

12/20/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.